Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label dose-escalation and cohort-expansion study of MH048 in relapsed/refractory B-cell malignancies
CTR20220700Phase 2Active
- Sponsor
- Minghui Pharmaceutical, Inc.
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MH048 in B-cell malignancy, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Richter's syndrome (RS), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), sponsored by Minghui Pharmaceutical, Inc.. Started Dec 2021; status: active.
02
Drugs
MH048
03
Conditions
B-cell malignancychronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)Richter's syndrome (RS)mantle cell lymphoma (MCL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20220700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220700.